YOUNG HOPES IN CARDIOLOGY
Dear collegues,
We invite you to a short symposium, full of new developments and practical recommendations, which will lead you into the world of making the right decisions at setting the diagnosis and treatment of pulmonary arterial hypertension. Patients with pulmonary hypertension can be encountered everywhere. That is why this symposium is suitable for all specialties.
You can attend the symposium in person or on-line. The lectures will be available on the platform for a whole month, so you can watch only part of the symposium live and the rest at a later date. After the symposium, it will be possible to obtain credit points by completing a questionnaire.
On the behalf of organisers,
Polona Mlakar
Pulmonary arterial hypertension was once a fatal disease. In majority of cases several years passed from the onset of symptoms to the diagnosis. After diagnosis, mortality was greater than 50% within three years.
Prostacyclin was the first effective specific drug. It was rarely used. The route of administration was intravenous, many times difficult and associated with complications. This was followed by the development of drugs that could be administered subcutaneously. Other specific drugs that can be taken orally have also been discovered.
Following the 3rd WHO Symposium on Pulmonary Hypertension in 2003 in Venice, Italy, a breakthrough in patient management occurred. It has become important to make the diagnosis early and correctly, to make the right decision for the treatment. A modern approach to treatment has evolved. Prognosis and quality of life has improved significantly. Pulmonary arterial hypertension became a chronic disease.
We are delighted to have experts from our neighbouring countries with us for the on-line symposium. We have been working with them for 20 years. During this time, we have established modern management of patients with pulmonary arterial hypertension.
Prof. dr. Irene Marthe Lang
Prof. dr. Nazzareno Galie
In particular, world-leading experts Prof. Irene Marthe Lang from AKH Vienna, Austria, and Prof. Nazzareno Galie from the University of Bologna, Italy, who has also been the lead expert for all these years for the development of the European guidelines, have played a key role in establishing this. They have helped us both in the management of complex patients and also regarding organisation of patient management. We used the expertise of both of them when we argued with the Health Insurance Fund why we urgently needed expensive specific medicines, for which we are extremely grateful to both of them.
We are also extremely grateful to all our experts and key people at the Health Insurance Fund, who heard our expert’s arguments and made it possible for us to follow all the European recommendations for the modern management of these patients.
Programme and organising committee:
Barbara Salobir, Polona Mlakar, Matevž Harlander
REGISTRATION
THE PROGRAM
11:00–11:10
Welcoming address,
Medical Director of the University Medical Centre Ljubljana
MODERN MANAGEMENT OF PAH: ROLE OF PROPER DIAGNOSTICS
(11:10 – 12:50):
CHAIR:
Wednesday, January 12, 2022
MONS after MONS 2021| 17:00
NOAK, Antiaggregation, Treatment of arterial hypertension
Thursday, January 13, 2022
MONS before MONS 2022 | 17:00– 19:30
POLYPRAGMASY
Moderator:Miha Šušteršič and Luka Lipar
Friday, January 14, 2022
Exhibition of openings| 13:40-15:30
New AHA-ACC guidelines for chest pain/Matjaž Bunc
Mechanisms of action of SGLT2, Inclisirana, PCSK-9, ARNI, vercigvata /Andraž Cerar
"Mons after Mons" Higlights: SGLT-2, Inclisar
High sensitivity ECG /Miha Šusteršič
Coronary sinus flow restrictor - CFR /Miha Mrak
Infections and the heart /Janez Tomažič
15:30-15:45 INTRODUCTION | Patient with stable coronary disease: Treatment trends /Matjaž Bunc
Symposium I | 15:45-17:15
THE LATEST APPROACHES TO LIMITING THE RISKS OF ATHEROSCLEROSIS
Moderator:Mišo Šabovič and Zlatko Fras
ESC 2021 Highlights: Limiting the risk of AS
Effects of statins, ezetimibe, PCSK9 inhibitors, included / Zlatko Fras
Overview of antidiabetic therapy, new drugs and clinical indications /Aleš Skvarča
Antithrombotic therapy / Gregor Tratar
Renal denervation (RDN), arterial hypertension / Dragan Kovačić
Optimal clinical practice - patient case /Miran Šebeštjen and Borut Jug
Questions and discussion/ Mišo Šabovič in Zlatko Fras
17:15-17:20 A break
Symposium II | 17:20-18:20
COMMON DILEMMA IN POLYMORBID PATIENTS
Moderators: Boris Krajačič, Simon Terseglav
Polypragmasy / Matej Marinšek
Measures in case of deterioration of kidney function / Jernej Pajek
Interactions between cardiac drugs, pollution and CVD diseases /Miran Brvar
Young people for young people: Polypragmatism / Miha Šusteršič
Questions and discussion/ Boris Krajačič, Simon Terseglav
18:20-18:35 A break
Symposium III| 18:35-19:50
UNSPECIFIED CHEST PAIN
Moderator:Matjaž Bunc and Miha Čerček
INOCA diagnostics (non-invasive INOCA diagnostics) /Borut Drnovšek
Nucleotide tests /Luka Ležaic
The role of CTA of the coronary arteries and MR of the heart /Tomaž Podlesnikar
Pulmonary hypertension / Polona Mlakar
Covid and the cardiovascular system / Gradecki outlet
Acute consequences of Covid-19 on the heart: UKC Lj / Andreja Černa Čerček
Questions and discussion /Matjaž Bunc and Miha Čerček
19:50-19:55 A break
Round table | 19:55-20:40
TREATMENT OF THE FUTURE
Moderator: Igor E. Bergant
Genetic diagnostics, genetic treatment /Borut Štrukelj, Borut Peterlin, Robert Zorec
Closing of the meeting and summary
11:10–11:40
11:40–11:50
11:50–12:00
12:00–12:10
12:10–12:20
12:20–12:30
12:30–12:50
Where we came from and where we are going in modern diagnostics of PAH /
Prof. Nazzareno Galie, Dept. of Cardiology, Professor of cardiology, Alma Mater Studiorum, University Bologna, Bologna, Italy; Vice-chairman of the Core Network PH of the European Reference Network—LUNG (ERN-LUNG), coordinator of the Guidelines and best Practice of Care committee of ERN-LUNG
Proper diagnostics in specialized centers /
Assist. Polona Mlakar, MD, PhD, Dept. for Pulmonary Diseases and Allergies, University Medical Centre Ljubljana, Slovenia
Role of right heart catheterisation – experiences from our specialized center /
David Lestan, MD, Dept. of Pulmonary Diseases and Allergies, University Medical Centre Ljubljana, Slovenia
Role of noninvasive diagnostic procedures - experiences from our specialized center /
Assist. Prof. Marta Cvijić, MD, PhD, Dept. of Cardiology, University Medical Centre Ljubljana, Slovenia
“PAH associated with connective tissue diseases – most vulnerable group of PAH patients” /
Assist. Prof. Antonija Hočevar, MD, PhD, Dept. of Rheumatology, University Medical Centre Ljubljana, Slovenia
“Role of cardiac echocardiography in the early detection of PAH in patients with connective tissue diseases – experiences from our specialized center”
Assist. Janez Toplišek, MD, PhD, Dept. of Cardiology, University Medical Centre Ljubljana, Slovenia
Round table with discussion /
All participants
MODERN MANAGEMENT OF PAH: ROLE OF PROPER DECISION MAKING FOR THERAPY
(13:00 – 15:30):
CHAIR:
Assist. Prof. Barbara Salobir, MD, PhD, Dept. of Pulmonary Diseases and Allergies, University Medical Centre Ljubljana, Slovenia, Assist. Polona Mlakar, MD, PhD, Dept. for Pulmonary Diseases and Allergies, University Medical Centre Ljubljana, Slovenia
13:00–13:30
13:30–13:45
13:45–14:00
14:00–14:15
14:15–14:30
14:30–14:45
14:45–15:00
15:00–15:20
15:20–15:30
Where we came from and where we are going in modern therapy of PAH /
Prof. Irene Lang, AKH Vienna, Dept. of Cardiology, AKH Vienna, Professor of Vascular Biology and Cardiology on Medical University of Vienna, Austria.
»Obstacles in implementation of the 2022 ESC/ERS guidelines on pulmonary hypertension in the routine clinical practice« /
Prof. Arsen Ristić, Division of Cardiology, University Clinical Center of Serbia, Belgrade, Serbia
»Parenteral prostacyclines – still the most effective therapy for PAH« /
Assist. Prof. Nika Skoro Sajer, Dept. of Cardiology, AKH Vienna, Austria
»Better possibilites for long term parenteral prostacyclin therapy with sc. pumps – experiences from AKH Vienna« /
Assist. Prof. Roza Badr-Eslam, Dept. of Cardiology, AKH Vienna, Austria.
»Proper decision for patient with vasoreactive PAH after clinical deterioration on high doses of calcium channel blockers« /
Prof. Jovan Matijašević, Institute for Pulmonary Diseases of Vojvodina, Dept. of Emergency Pulmonology, Sremska Kamenica, Serbia.
»Long term benefit of combined, oral, specific therapy for PAH« /
Prim. Ana Hećimović, MD, PhD, , Clinic for lung diseases, University Hospital Centre Zagreb, Croatia
Novelities in therapy of PAH important for clinical practice /
Assist. Prof. Barbara Salobir, MD, PhD, Dept. of Pulmonary Diseases and Allergies, University Medical Centre Ljubljana, Slovenia
Round table with discussion /
All participants
Closing remarks /
Assist. Prof. Matevž Harlander, MD, PhD, Dept. of Pulmonary Diseases and Allergies, University Medical Centre Ljubljana, Slovenia
Organizer:
SiNAPSA - Slovenian Neuroscience Association
The
Technical support:
Plant E-coopedu
The
Contact :
Technical and organizational support:
Institute for Professional Education and Innovation Support E-coopedu
Web page:
